East Hanover, June 13, 2005 Researchers reported yesterday that in a two-year, controlled study people with type 2 diabetes receiving Starlix (nateglinide) in combination with metformin experienced equivalent levels of overall blood glucose control and a lower incidence and severity of hypoglycemia compared to the those taking the commonly used sulfonylurea agent, glyburide, in combination with metformin. This trial is the first to prospectively evaluate the long-term safety and efficacy of the Starlix/metformin combination for two years. Researchers also observed that treatment with Starlix plus metformin was weight neutral, while participants in the glyburide/metformin arm of the trial gained about 1 kg over the two-year study period. These data were presented yesterday at the Annual Scientific Sessions of the American Diabetes Association.
"Physicians and patients are always looking for improved treatment strategies and combinations to help them achieve their target blood glucose goals," said John Gerich, M.D., University of Rochester. "Results from this trial have important clinical implications: In the past, the risk of hypoglycemia, or very low blood sugar, has been a limiting factor for early and aggressive therapy. Hypoglycemia can be life threatening for people with diabetes. There were 50 percent fewer cases of hypoglycemia with the Starlix/metformin combination."
Consistent with the mechanism of action of Starlix, which mimics the body's natural response to meals, the Starlix plus metformin group had greater reductions in post-meal glucose levels (post prandial glucose or PPG) than the glyburide and metformin group.
"Starlix's ability to lower overall blood glucose (or HbA1c) by controlling PPG is complementary to metformin's action, which lowers fasting plasma glucose levels (FPG)," continued Dr. Gerich. "A drug combination that reduces HbA1c by lowering both PPG and FPG offers doctors and patients an effective way to rePage: 1 2 3 Related medicine news :1
Contact: Alison Poole
. Rising skin cancer rates are more likely to affect wealthy people, says 12-year review2
. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals3
. Penn study finds pro-death proteins required to regulate healthy immune function4
. New study shows promise in reducing surgical risks associated with surgical bleeding5
. New study counts the economic cost of persistent pain in Australia6
. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA7
. Most seniors now have drug coverage, U-M study shows8
. To gain muscle and lose fat, drink milk: study9
. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests10
. Even older women at high risk have little interest in being tested for HIV, study finds11
. Metabolic study in mice could lead to good cholesterol boosters